Current Report Filing (8-k)
April 04 2016 - 4:43PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): April 1, 2016
IMMUNOCLIN CORPORATION
(Exact name of registrant as specified in
its charter)
Nevada
|
000-54738
|
32-0337695
|
(State or Other Jurisdiction
|
(Commission
|
(I.R.S. Employer
|
of Incorporation)
|
File Number)
|
Identification No.)
|
1420 N Street, Suite 102, NW, Washington,
DC 20005, USA
(Address of Principal Executive Office)
(Zip Code)
202-838-8141
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 4.01
|
Change in Registrant’s Certifying Accountant
|
On April 1, 2016, the
Board of Directors of Immunoclin Corporation (the “Company”) dismissed Turner, Stone & Company (“Turner”)
as the Company’s independent registered public accounting firm, not for cause or any disagreement, effectively immediately.
The Company engaged
Turner in July 2014 following the Company’s dismissal of its prior public accounting firm. Turner did not report on the Company’s
financial statements for the year ended January 31, 2015 since the Company has not completed the audit of its financial statements
for that fiscal period. During the term of Turner’s engagement as the Company’s public accounting firm and through
the effective date of Turner’s dismissal, (i) there were no disagreements with Turner on any matter of accounting principles
or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Turner’s
satisfaction, would have caused Turner to make reference to the subject matter of such disagreements in its reports on the Company’s
consolidated financial statements for such year, and (ii) there were no reportable events as defined in Item 304(a)(1)(v) of Regulation
S-K.
The Company has provided
Turner with a copy of the foregoing disclosures and requested that it furnish a letter to the Securities and Exchange Commission
stating whether or not it agrees with the above statements. A copy of such letter is filed as Exhibit 16.1 to this Current Report
on Form 8-K.
|
16.1
|
Turner Letter dated April 4, 2016
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
hereunto duly authorized.
|
By:
|
/s/ Dr. Dorothy Bray
|
|
|
Dr. Dorothy Bray, President and CEO
|
Date: April
4, 2016